VIR logo

Vir Biotechnology (VIR) Company Overview

Profile

Full Name:

Vir Biotechnology, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 11, 2019

Indexes:

Not included

Description:

Vir Biotechnology, Inc. is an American clinical immunology company. Registered in 2016 in the state of Delaware. Headquarters are located in San Francisco, California. The company specializes in developing methods based on a combination of immune responses and advanced technologies for the treatment and prevention of serious diseases such as hepatitis B or HBV, influenza A, severe acute respiratory syndrome, coronavirus 2 or SARS-CoV-2, human immunodeficiency virus or HIV, and tuberculosis. Drug candidates are developed on four technological platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or miRNA, through internal development, collaborations, and acquisitions.

Key Details

Price

$10.01

Annual Revenue

$39.49 M(-97.50% YoY)

Annual EPS

-$4.59(-219.84% YoY)

Annual ROE

-33.53%

Beta

1.63

Events Calendar

Earnings

Next earnings date:

Feb 21, 2025

Recent quarterly earnings:

Oct 31, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 31, 25 HC Wainwright & Co.
Buy
Jan 13, 25 Leerink Partners
Outperform
Jan 10, 25 HC Wainwright & Co.
Buy
Jan 9, 25 Morgan Stanley
Overweight
Jan 9, 25 JP Morgan
Neutral
Nov 20, 24 Needham
Buy
Nov 20, 24 HC Wainwright & Co.
Buy
Nov 4, 24 HC Wainwright & Co.
Buy
Nov 4, 24 Barclays
Overweight
Nov 1, 24 Needham
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Vir Biotechnology: A Rocket Off Phase 1 Data
Vir Biotechnology: A Rocket Off Phase 1 Data
Vir Biotechnology: A Rocket Off Phase 1 Data
VIR
seekingalpha.comJanuary 9, 2025

Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation.

VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
VIR
zacks.comJanuary 9, 2025

Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
VIR
businesswire.comJanuary 8, 2025

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co.

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
VIR
seekingalpha.comDecember 13, 2024

VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25.

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
VIR
businesswire.comDecember 12, 2024

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AAS.

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
VIR
businesswire.comNovember 18, 2024

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at A.

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
VIR
businesswire.comNovember 15, 2024

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (

Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript
VIR
seekingalpha.comOctober 31, 2024

Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Eric Joseph - JPMorgan Mike Ulz - Morgan Stanley Gena Wang - Barclays Alec Stranahan - Bank of America Nikola Gasic - Leerink Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co.

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
VIR
businesswire.comOctober 17, 2024

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors.

Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024
VIR
247wallst.comAugust 6, 2024

24/7 Wall St. Insights Market pullbacks can make nervous investors leery of investing in industries that are speculative in nature.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Vir Biotechnology?
  • Does Vir Biotechnology pay dividends?
  • What sector is Vir Biotechnology in?
  • What industry is Vir Biotechnology in?
  • What country is Vir Biotechnology based in?
  • When did Vir Biotechnology go public?
  • Is Vir Biotechnology in the S&P 500?
  • Is Vir Biotechnology in the NASDAQ 100?
  • Is Vir Biotechnology in the Dow Jones?
  • When was Vir Biotechnology's last earnings report?
  • When does Vir Biotechnology report earnings?
  • Should I buy Vir Biotechnology stock now?

What is the ticker symbol for Vir Biotechnology?

The ticker symbol for Vir Biotechnology is NASDAQ:VIR

Does Vir Biotechnology pay dividends?

No, Vir Biotechnology does not pay dividends

What sector is Vir Biotechnology in?

Vir Biotechnology is in the Healthcare sector

What industry is Vir Biotechnology in?

Vir Biotechnology is in the Biotechnology industry

What country is Vir Biotechnology based in?

Vir Biotechnology is headquartered in United States

When did Vir Biotechnology go public?

Vir Biotechnology's initial public offering (IPO) was on October 11, 2019

Is Vir Biotechnology in the S&P 500?

No, Vir Biotechnology is not included in the S&P 500 index

Is Vir Biotechnology in the NASDAQ 100?

No, Vir Biotechnology is not included in the NASDAQ 100 index

Is Vir Biotechnology in the Dow Jones?

No, Vir Biotechnology is not included in the Dow Jones index

When was Vir Biotechnology's last earnings report?

Vir Biotechnology's most recent earnings report was on Oct 31, 2024

When does Vir Biotechnology report earnings?

The next expected earnings date for Vir Biotechnology is Feb 21, 2025

Should I buy Vir Biotechnology stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions